ArticleBMC musculoskeletal disorders2025
The role of serum zinc and MicroRNAs in osteoporosis: insights into bone metabolism and potential diagnostic markers.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZinc (Zn) levels are reportedly lower in osteoporosis patients and may be linked to bone health. MicroRNAs (miRNAs) have also been implicated in the regulation of bone remodeling. This study aims to investigate the role of selected miRNAs and their potential interplay with Zn in the pathogenesis of osteoporosis.
methodsIn this case-control study, 50 patients with osteoporosis and 50 healthy controls were recruited. The serum transcript levels of miRNAs were assessed using Real-time PCR.
resultsLevels of Zn was significantly (P = 0.0047) lower in the serum samples from osteoporosis patients in comparison to the healthy controls. The transcript level of miR-34a-5p (Fold change = 2.59, P = 0.008) and miR-335-5p (Fold change = 1.90, P = 0.013) was upregulated significantly in the serum samples of patients with osteoporosis compared to that of the healthy controls. Zn level in osteoporosis patients had significant negative correlation with transcript levels of miR-335-5p (r= -0.24, P = 0.037). Zn level had positive correlation with Z and T-scores and BMD of hip, spine, and femur. A negative correlation (r= -0.28 P = 0.044) was detected between transcript level of miR-34a-5p and femur BMD. There was a significant negative correlation between transcript level of miR-335-5p and hip BMD (r= -0.19 P = 0.038). miR-34a-5p and miR-335-5p showed diagnostic potential.
conclusionsThe findings suggest a potential interplay between Zn and miRNAs in the regulation of bone metabolism in osteoporosis patients. Zn and miRNAs may serve as biomarkers for bone health and a therapeutic target in osteoporosis management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.